Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group
- 1 August 2020
- journal article
- research article
- Published by Elsevier in European Urology Oncology
- Vol. 3 (4) , 455-463
Abstract
No abstract availableKeywords
Funding Information
- Merck
- Ferring
- Bayer
- Astellas Pharma Canada
- Sanofi
This publication has 57 references indexed in Scilit:
- Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trialThe Lancet, 2018
- Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate CancerNew England Journal of Medicine, 2018
- Apalutamide Treatment and Metastasis-free Survival in Prostate CancerNew England Journal of Medicine, 2018
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate CancerNew England Journal of Medicine, 2017
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone TherapyNew England Journal of Medicine, 2017
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialThe Lancet, 2016
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerNew England Journal of Medicine, 2015
- Enzalutamide in Metastatic Prostate Cancer before ChemotherapyNew England Journal of Medicine, 2014
- Abiraterone in Metastatic Prostate Cancer without Previous ChemotherapyNew England Journal of Medicine, 2013
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate CancerNew England Journal of Medicine, 2004